SLC5A2 and type 2 diabetes mellitus: In four large-scale clinical trials involving > 36,000 patients with type 2 diabetes followed for 2–5 years who largely did not have a diagnosis of heart failure at the time of study entry, patients treated with a SGLT2 inhibitor experienced a ≈ 25–35% lower risk of hospitalization for heart failure [1].